RU2010119950A - Комплексы s100a12 c устойчивостью к эдта (erac) - Google Patents
Комплексы s100a12 c устойчивостью к эдта (erac) Download PDFInfo
- Publication number
- RU2010119950A RU2010119950A RU2010119950/15A RU2010119950A RU2010119950A RU 2010119950 A RU2010119950 A RU 2010119950A RU 2010119950/15 A RU2010119950/15 A RU 2010119950/15A RU 2010119950 A RU2010119950 A RU 2010119950A RU 2010119950 A RU2010119950 A RU 2010119950A
- Authority
- RU
- Russia
- Prior art keywords
- specified
- sample
- erac
- antibody
- kit
- Prior art date
Links
- 102000058242 S100A12 Human genes 0.000 title claims 11
- 108700016890 S100A12 Proteins 0.000 title claims 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 title claims 5
- 239000000523 sample Substances 0.000 claims abstract 65
- 239000002245 particle Substances 0.000 claims abstract 54
- 239000007790 solid phase Substances 0.000 claims abstract 19
- 102000004169 proteins and genes Human genes 0.000 claims abstract 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract 15
- 229910021645 metal ion Inorganic materials 0.000 claims abstract 13
- 238000001514 detection method Methods 0.000 claims abstract 11
- 150000001875 compounds Chemical class 0.000 claims abstract 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract 4
- 239000000975 dye Substances 0.000 claims abstract 4
- 108091033319 polynucleotide Proteins 0.000 claims abstract 4
- 102000040430 polynucleotide Human genes 0.000 claims abstract 4
- 239000002157 polynucleotide Substances 0.000 claims abstract 4
- 239000000427 antigen Substances 0.000 claims abstract 3
- 102000036639 antigens Human genes 0.000 claims abstract 3
- 108091007433 antigens Proteins 0.000 claims abstract 3
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims abstract 3
- 239000007850 fluorescent dye Substances 0.000 claims abstract 3
- 150000004676 glycans Chemical class 0.000 claims abstract 3
- 229920001282 polysaccharide Polymers 0.000 claims abstract 3
- 239000005017 polysaccharide Substances 0.000 claims abstract 3
- 108090001008 Avidin Proteins 0.000 claims abstract 2
- 102000004856 Lectins Human genes 0.000 claims abstract 2
- 108090001090 Lectins Proteins 0.000 claims abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract 2
- 108010090804 Streptavidin Proteins 0.000 claims abstract 2
- 101710120037 Toxin CcdB Proteins 0.000 claims abstract 2
- 229960002685 biotin Drugs 0.000 claims abstract 2
- 235000020958 biotin Nutrition 0.000 claims abstract 2
- 239000011616 biotin Substances 0.000 claims abstract 2
- 230000002255 enzymatic effect Effects 0.000 claims abstract 2
- 230000002068 genetic effect Effects 0.000 claims abstract 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000010931 gold Substances 0.000 claims abstract 2
- 229910052737 gold Inorganic materials 0.000 claims abstract 2
- 239000003102 growth factor Substances 0.000 claims abstract 2
- 239000005556 hormone Substances 0.000 claims abstract 2
- 229940088597 hormone Drugs 0.000 claims abstract 2
- 239000004816 latex Substances 0.000 claims abstract 2
- 229920000126 latex Polymers 0.000 claims abstract 2
- 239000002523 lectin Substances 0.000 claims abstract 2
- 239000006249 magnetic particle Substances 0.000 claims abstract 2
- 125000005439 maleimidyl group Chemical class C1(C=CC(N1*)=O)=O 0.000 claims abstract 2
- 150000002772 monosaccharides Chemical class 0.000 claims abstract 2
- 150000002482 oligosaccharides Polymers 0.000 claims abstract 2
- 230000002285 radioactive effect Effects 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 82
- 108090000765 processed proteins & peptides Proteins 0.000 claims 42
- 229920001184 polypeptide Polymers 0.000 claims 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims 41
- 210000001124 body fluid Anatomy 0.000 claims 16
- 239000010839 body fluid Substances 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 15
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 10
- 239000002738 chelating agent Substances 0.000 claims 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 7
- 230000002526 effect on cardiovascular system Effects 0.000 claims 7
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000000178 monomer Substances 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 4
- 238000004458 analytical method Methods 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 238000012544 monitoring process Methods 0.000 claims 4
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- -1 carboxyfluorecein Chemical compound 0.000 claims 3
- 239000012530 fluid Substances 0.000 claims 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims 3
- 230000028327 secretion Effects 0.000 claims 3
- 238000012360 testing method Methods 0.000 claims 3
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 3
- 230000009261 transgenic effect Effects 0.000 claims 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 2
- 101000693049 Homo sapiens Protein S100-A14 Proteins 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 102100026298 Protein S100-A14 Human genes 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 239000007795 chemical reaction product Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims 2
- 238000011496 digital image analysis Methods 0.000 claims 2
- 238000011010 flushing procedure Methods 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 230000001900 immune effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 201000011461 pre-eclampsia Diseases 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 210000001179 synovial fluid Anatomy 0.000 claims 2
- 201000009482 yaws Diseases 0.000 claims 2
- FVNKQMCPAAGEOO-UHFFFAOYSA-N 1-fluoroacridine Chemical compound C1=CC=C2C=C3C(F)=CC=CC3=NC2=C1 FVNKQMCPAAGEOO-UHFFFAOYSA-N 0.000 claims 1
- 208000010370 Adenoviridae Infections Diseases 0.000 claims 1
- 229920000936 Agarose Polymers 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003445 Ascites Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 241000193738 Bacillus anthracis Species 0.000 claims 1
- 208000003508 Botulism Diseases 0.000 claims 1
- 208000007198 Bovine Brucellosis Diseases 0.000 claims 1
- 241001148106 Brucella melitensis Species 0.000 claims 1
- 241001148111 Brucella suis Species 0.000 claims 1
- 206010006500 Brucellosis Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 108010052500 Calgranulin A Proteins 0.000 claims 1
- 108010052495 Calgranulin B Proteins 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 206010007134 Candida infections Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010007882 Cellulitis Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 201000006082 Chickenpox Diseases 0.000 claims 1
- 206010008631 Cholera Diseases 0.000 claims 1
- 241000223205 Coccidioides immitis Species 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 229920002271 DEAE-Sepharose Polymers 0.000 claims 1
- 206010012504 Dermatophytosis Diseases 0.000 claims 1
- 206010014666 Endocarditis bacterial Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 201000000297 Erysipelas Diseases 0.000 claims 1
- 206010062488 Erythema migrans Diseases 0.000 claims 1
- 108050001049 Extracellular proteins Proteins 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 229920002527 Glycogen Polymers 0.000 claims 1
- 206010018612 Gonorrhoea Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 208000001688 Herpes Genitalis Diseases 0.000 claims 1
- 101000985261 Homo sapiens Hornerin Proteins 0.000 claims 1
- 101000685712 Homo sapiens Protein S100-A1 Proteins 0.000 claims 1
- 101000653788 Homo sapiens Protein S100-A11 Proteins 0.000 claims 1
- 101000693054 Homo sapiens Protein S100-A13 Proteins 0.000 claims 1
- 101000693050 Homo sapiens Protein S100-A16 Proteins 0.000 claims 1
- 101000685726 Homo sapiens Protein S100-A2 Proteins 0.000 claims 1
- 101000685725 Homo sapiens Protein S100-A3 Proteins 0.000 claims 1
- 101000685719 Homo sapiens Protein S100-A5 Proteins 0.000 claims 1
- 101000727775 Homo sapiens Protein S100-A7A Proteins 0.000 claims 1
- 206010053317 Hydrophobia Diseases 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 206010021531 Impetigo Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000007764 Legionnaires' Disease Diseases 0.000 claims 1
- 206010024238 Leptospirosis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000032376 Lung infection Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 201000005505 Measles Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 241001460074 Microsporum distortum Species 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029443 Nocardia Infections Diseases 0.000 claims 1
- 241000187678 Nocardia asteroides Species 0.000 claims 1
- 206010029444 Nocardiosis Diseases 0.000 claims 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims 1
- 201000005702 Pertussis Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 206010034839 Pharyngitis streptococcal Diseases 0.000 claims 1
- 206010035718 Pneumonia legionella Diseases 0.000 claims 1
- 208000000474 Poliomyelitis Diseases 0.000 claims 1
- 206010036422 Postpartum sepsis Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 102100023097 Protein S100-A1 Human genes 0.000 claims 1
- 102100029796 Protein S100-A10 Human genes 0.000 claims 1
- 102100029811 Protein S100-A11 Human genes 0.000 claims 1
- 102100025670 Protein S100-A13 Human genes 0.000 claims 1
- 102100026296 Protein S100-A16 Human genes 0.000 claims 1
- 102100023089 Protein S100-A2 Human genes 0.000 claims 1
- 102100023090 Protein S100-A3 Human genes 0.000 claims 1
- 102100023088 Protein S100-A5 Human genes 0.000 claims 1
- 102100032442 Protein S100-A8 Human genes 0.000 claims 1
- 102100032420 Protein S100-A9 Human genes 0.000 claims 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 claims 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 claims 1
- 208000020264 Puerperal Infection Diseases 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 206010037742 Rabies Diseases 0.000 claims 1
- 206010062237 Renal impairment Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 102000005881 S100 Calcium Binding Protein A6 Human genes 0.000 claims 1
- 108010005260 S100 Calcium Binding Protein A6 Proteins 0.000 claims 1
- 102000005871 S100 Calcium Binding Protein A7 Human genes 0.000 claims 1
- 108010005256 S100 Calcium Binding Protein A7 Proteins 0.000 claims 1
- 102000007460 S100 Calcium-Binding Protein A4 Human genes 0.000 claims 1
- 108010085149 S100 Calcium-Binding Protein A4 Proteins 0.000 claims 1
- 108010015695 S100 calcium binding protein A10 Proteins 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010043376 Tetanus Diseases 0.000 claims 1
- 208000002474 Tinea Diseases 0.000 claims 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 201000005485 Toxoplasmosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000034784 Tularaemia Diseases 0.000 claims 1
- 208000037386 Typhoid Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 206010046980 Varicella Diseases 0.000 claims 1
- 206010062910 Vascular infections Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000000260 Warts Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000003152 Yellow Fever Diseases 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 claims 1
- BGLGAKMTYHWWKW-UHFFFAOYSA-N acridine yellow Chemical compound [H+].[Cl-].CC1=C(N)C=C2N=C(C=C(C(C)=C3)N)C3=CC2=C1 BGLGAKMTYHWWKW-UHFFFAOYSA-N 0.000 claims 1
- 201000007691 actinomycosis Diseases 0.000 claims 1
- 238000000246 agarose gel electrophoresis Methods 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 238000005349 anion exchange Methods 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 210000003567 ascitic fluid Anatomy 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000009361 bacterial endocarditis Diseases 0.000 claims 1
- 239000007982 barbital buffer Substances 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 238000011088 calibration curve Methods 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000003984 candidiasis Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 210000003756 cervix mucus Anatomy 0.000 claims 1
- 201000004308 chancroid Diseases 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000013507 chronic prostatitis Diseases 0.000 claims 1
- 201000003486 coccidioidomycosis Diseases 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 238000010668 complexation reaction Methods 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 229960000956 coumarin Drugs 0.000 claims 1
- 235000001671 coumarin Nutrition 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 238000011161 development Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- XVLXYDXJEKLXHN-UHFFFAOYSA-M dioc6 Chemical compound [I-].O1C2=CC=CC=C2[N+](CCCCCC)=C1C=CC=C1N(CCCCCC)C2=CC=CC=C2O1 XVLXYDXJEKLXHN-UHFFFAOYSA-M 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000001848 dysentery Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 claims 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 claims 1
- 208000001606 epiglottitis Diseases 0.000 claims 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 claims 1
- 229940011411 erythrosine Drugs 0.000 claims 1
- 235000012732 erythrosine Nutrition 0.000 claims 1
- 239000004174 erythrosine Substances 0.000 claims 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 claims 1
- 229960005542 ethidium bromide Drugs 0.000 claims 1
- 210000000416 exudates and transudate Anatomy 0.000 claims 1
- 210000003608 fece Anatomy 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
- FRIPRWYKBIOZJU-UHFFFAOYSA-N fluorone Chemical compound C1=CC=C2OC3=CC(=O)C=CC3=CC2=C1 FRIPRWYKBIOZJU-UHFFFAOYSA-N 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 201000004946 genital herpes Diseases 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- 208000001786 gonorrhea Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 239000001341 hydroxy propyl starch Substances 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 229940050526 hydroxyethylstarch Drugs 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- JGIDSJGZGFYYNX-YUAHOQAQSA-N indian yellow Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC1=CC=C(OC=2C(=C(O)C=CC=2)C2=O)C2=C1 JGIDSJGZGFYYNX-YUAHOQAQSA-N 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 201000006747 infectious mononucleosis Diseases 0.000 claims 1
- 201000007119 infective endocarditis Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000000025 natural resin Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- 229960002378 oftasceine Drugs 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000000906 photoactive agent Substances 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 208000007865 relapsing fever Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 201000005404 rubella Diseases 0.000 claims 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229920001059 synthetic polymer Polymers 0.000 claims 1
- 208000006379 syphilis Diseases 0.000 claims 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 201000008297 typhoid fever Diseases 0.000 claims 1
- 206010061393 typhus Diseases 0.000 claims 1
- 208000000143 urethritis Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 230000003313 weakening effect Effects 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rehabilitation Therapy (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99965307P | 2007-10-19 | 2007-10-19 | |
| DKPA200701511 | 2007-10-19 | ||
| DKPA200701511 | 2007-10-19 | ||
| US60/999,653 | 2007-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010119950A true RU2010119950A (ru) | 2011-11-27 |
Family
ID=40292524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010119950/15A RU2010119950A (ru) | 2007-10-19 | 2008-10-17 | Комплексы s100a12 c устойчивостью к эдта (erac) |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20110312922A1 (enExample) |
| EP (1) | EP2210102A2 (enExample) |
| JP (1) | JP2011502244A (enExample) |
| CN (1) | CN101903775A (enExample) |
| AU (1) | AU2008313688A1 (enExample) |
| CA (1) | CA2702533A1 (enExample) |
| IL (1) | IL205039A0 (enExample) |
| RU (1) | RU2010119950A (enExample) |
| WO (1) | WO2009050277A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8854101A1 (es) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa |
| WO2010145883A1 (en) | 2009-05-07 | 2010-12-23 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators |
| CN102706971A (zh) * | 2010-12-09 | 2012-10-03 | 江南大学 | 一种以离子液体作为添加剂的反向微乳毛细管电动色谱分析化妆品中的糖皮质激素的方法 |
| CN103460045B (zh) | 2011-04-05 | 2016-01-20 | 奥林巴斯株式会社 | 胰脏检查方法及胰脏检查试剂盒 |
| WO2013167727A2 (en) * | 2012-05-11 | 2013-11-14 | Westfaelische Wilhelms-Universitaet Muenster | Method for determining arthritis relapse risk |
| CN107576785A (zh) * | 2017-08-25 | 2018-01-12 | 广州市雷德生物科技有限公司 | 一种样本处理液及其应用 |
| US11905561B2 (en) | 2018-10-16 | 2024-02-20 | King Faisal Specialist Hospital & Research Centre | Method for diagnosing or treating pulmonary fibrosis using S100A13 protein |
| CN119838011A (zh) * | 2024-12-10 | 2025-04-18 | 内蒙古自治区中蒙医药研究院 | Slc9a1蛋白和s100a2蛋白作为作用靶点在制备治疗原发性高血压的药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0731166A3 (en) * | 1995-03-06 | 1997-12-29 | Tonen Corporation | Novel calcium-binding proteins |
| US6790443B2 (en) * | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
| WO2000020621A1 (en) * | 1998-10-06 | 2000-04-13 | The Trustees Of Columbia University In The City Of New York | Extracellular novel rage binding protein (en-rage) and uses thereof |
| US20030224386A1 (en) * | 2001-12-19 | 2003-12-04 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis |
| US20030175713A1 (en) * | 2002-02-15 | 2003-09-18 | Clemens Sorg | Method for diagnosis of inflammatory diseases using CALGRANULIN C |
| US20070148704A1 (en) * | 2005-10-06 | 2007-06-28 | Ursula Klause | Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis |
-
2008
- 2008-10-17 CA CA2702533A patent/CA2702533A1/en not_active Abandoned
- 2008-10-17 US US12/738,579 patent/US20110312922A1/en not_active Abandoned
- 2008-10-17 CN CN2008801122278A patent/CN101903775A/zh active Pending
- 2008-10-17 WO PCT/EP2008/064058 patent/WO2009050277A2/en not_active Ceased
- 2008-10-17 EP EP08840332A patent/EP2210102A2/en not_active Withdrawn
- 2008-10-17 AU AU2008313688A patent/AU2008313688A1/en not_active Abandoned
- 2008-10-17 RU RU2010119950/15A patent/RU2010119950A/ru not_active Application Discontinuation
- 2008-10-17 JP JP2010529401A patent/JP2011502244A/ja active Pending
-
2010
- 2010-04-13 IL IL205039A patent/IL205039A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101903775A (zh) | 2010-12-01 |
| WO2009050277A2 (en) | 2009-04-23 |
| JP2011502244A (ja) | 2011-01-20 |
| CA2702533A1 (en) | 2009-04-23 |
| IL205039A0 (en) | 2010-11-30 |
| EP2210102A2 (en) | 2010-07-28 |
| AU2008313688A1 (en) | 2009-04-23 |
| US20110312922A1 (en) | 2011-12-22 |
| WO2009050277A3 (en) | 2009-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Poullis et al. | Emerging role of calprotectin in gastroenterology | |
| JP6971218B2 (ja) | 横断組織切片のユーザー定義領域における遺伝子発現の同時定量 | |
| RU2010119950A (ru) | Комплексы s100a12 c устойчивостью к эдта (erac) | |
| RU2630608C2 (ru) | Рецептор фолиевой кислоты альфа в качестве диагностического и прогностического маркера злокачественных опухолей, экспрессирующих рецептор фолиевой кислоты альфа | |
| EP2069534A1 (en) | Methods and systems for detecting and/or sorting targets | |
| US20180238890A1 (en) | Methods and materials for detection, diagnosis and management of ovarian cancer | |
| JP2011502244A5 (enExample) | ||
| JP6104796B2 (ja) | 方法、アレイ、およびこれらの使用 | |
| US20130252839A1 (en) | Markers of primary graft dysfunction | |
| JP2021535410A (ja) | 全自動化学発光分析装置に基づく血清ｔｋ１検出キット | |
| JP2021181994A (ja) | 腎疾患の検出方法 | |
| WO2016195051A1 (ja) | 膵がんを診断するための血漿バイオマーカーパネル | |
| CN102507938B (zh) | 一种肝癌转移预测定量抗体芯片及试剂盒 | |
| CN113728233B (zh) | 用于生物样品中的游离aim的免疫分析方法和分析试剂盒 | |
| CN111610330A (zh) | 使用自身抗体-抗原结合物诊断肺癌的免疫学组合物，肺癌诊断方法以及肺癌诊断试剂盒 | |
| JPWO2016072464A1 (ja) | デオキシハイプシン・シンターゼ遺伝子を指標として用いる動脈硬化及びがんの検出方法 | |
| CN108738347B (zh) | 辅助肝细胞癌患者的再发风险预测的方法、装置、计算机程序制品及试剂盒 | |
| EP3924736A1 (en) | Compositions and methods for diagnosing and assessing rheumatoid arthritis | |
| JP7606464B2 (ja) | 光切断リンカーの光切断効率向上方法、光切断リンカー結合磁性粒子、並びに、対象物質を測定する測定方法及びこれに用いるためのキット | |
| JP7315965B2 (ja) | ウィルス性肝癌の検出方法 | |
| CN113447657B (zh) | 一种检测抗乌头酸水合酶-IgG抗体的检测试剂盒 | |
| WO2016040178A1 (en) | Methods for colon hyperproliferative disorder detection, prognosis, and diagnosis | |
| CN119619497A (zh) | 使用抗原检测抗体 | |
| CN120989088A (zh) | 特异性识别血清甲胎蛋白的核酸适配体及其用途 | |
| CN118076895A (zh) | 在生化测定中重复使用测试固体表面的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130826 |